{"id":536,"date":"2026-03-13T08:21:36","date_gmt":"2026-03-13T11:21:36","guid":{"rendered":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/?p=536"},"modified":"2026-05-04T11:48:45","modified_gmt":"2026-05-04T14:48:45","slug":"immunotherapy-wasp","status":"publish","type":"post","link":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/2026\/03\/13\/immunotherapy-wasp\/","title":{"rendered":"Project aims to improve immunotherapy for the treatment of wasp venom allergy"},"content":{"rendered":"\n<p class=\"eplus-wrapper\">Recently accredited as a supervisor in the <a href=\"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/farmacologia-da-unicamp\/\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/farmacologia-da-unicamp\/\" rel=\"noreferrer noopener\">Graduate Program in Pharmacology at UNICAMP<\/a>, <a href=\"https:\/\/lattes.cnpq.br\/2776633556618117\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/lattes.cnpq.br\/2776633556618117\" rel=\"noreferrer noopener\">Prof. Dr. Lu\u00eds Gustavo Romani Fernandes<\/a> investigates ways to improve immunotherapy for the treatment of wasp venom allergy in Brazil.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">In this article, we take a closer look at his <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">current research<\/mark><\/strong>, presenting its <strong>challenges<\/strong> and its <strong>relevance<\/strong> to society. The article is also an invitation for those interested in joining Prof. Lu\u00eds\u2019s research group, as he is currently seeking <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">new master\u2019s and doctoral students<\/mark><\/strong>, as well as technical training fellows.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">Prof. Lu\u00eds holds a <strong>degree in Biological Sciences<\/strong> and a <strong>PhD in Genetics and Molecular Biology<\/strong>, with a <strong>specialization in Immunology<\/strong>, from <strong>UNICAMP<\/strong>. He also completed <strong>postdoctoral training at UNICAMP<\/strong> in the <strong>Laboratory of Translational Immunology (LIT)<\/strong> at the <strong>School of Medical Sciences (FCM)<\/strong>, coordinated by <a href=\"https:\/\/lattes.cnpq.br\/8962594483120494\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/lattes.cnpq.br\/8962594483120494\" rel=\"noreferrer noopener\">Prof. Dr. Ricardo de Lima Zollner<\/a>, and more recently at the <strong>Laboratory of Dermatology and Experimental Allergy<\/strong> at <a href=\"https:\/\/www.uni-giessen.de\/en\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/www.uni-giessen.de\/en\" rel=\"noreferrer noopener\">Justus Liebig University<\/a> (Giessen, Germany). He is currently a researcher and biologist at the LIT. Since his doctoral studies, he has been investigating the <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">regulation of the immune response<\/mark><\/strong>.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">Today, Prof. Lu\u00eds\u2019s main line of investigation focuses on <strong>evaluating the cellular and molecular mechanisms<\/strong> <strong>involved in the regulation and activation of innate and adaptive immunity directed at allergens present in the venoms of Hymenoptera (bees, wasps, and ants)<\/strong>. Within this line of research, he holds a research grant from FAPESP (process no. <a href=\"https:\/\/bv.fapesp.br\/pt\/auxilios\/117301\/avaliacao-do-potencial-uso-de-variantes-hipoalergenicas-derivadas-dos-alergenos-poly-p-1-e-poly-p-5-\/?q=24\/23516-7\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/bv.fapesp.br\/pt\/auxilios\/117301\/avaliacao-do-potencial-uso-de-variantes-hipoalergenicas-derivadas-dos-alergenos-poly-p-1-e-poly-p-5-\/?q=24\/23516-7\" rel=\"noreferrer noopener\">24\/23516-7<\/a>) entitled: <strong>\u201cEvaluation of the potential use of hypoallergenic variants derived from the Poly p 1 and Poly p 5 allergens from the venom of the wasp <em>Polybia paulista<\/em> in allergen-specific immunotherapy protocols.\u201d<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center eplus-wrapper has-vivid-cyan-blue-color has-text-color has-link-color has-large-font-size wp-elements-7832cbf7285f594f50dd8b96af2a17dc\">When a sting can become fatal<\/h2>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio eplus-wrapper\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"MY GIRL [1991] - Official Trailer (HD)\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/KSyKO0Lklmo?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p class=\"eplus-wrapper\">Anyone who has watched the 1991 film <em><a href=\"https:\/\/www.imdb.com\/pt\/title\/tt0102492\/\" data-type=\"link\" data-id=\"https:\/\/www.imdb.com\/pt\/title\/tt0102492\/\" target=\"_blank\" rel=\"noreferrer noopener\">My Girl<\/a><\/em> may still carry emotional memories of <strong>one of the most unexpected deaths in cinema<\/strong>. If you haven\u2019t seen it yet, <strong>I\u2019m sorry for the spoiler<\/strong>. In the movie, we follow the friendship between Vada (played by Anna Chlumsky) and Thomas (Macaulay Culkin). The children\u2019s touching story comes to an abrupt end when <strong>Thomas is attacked by a swarm of bees<\/strong>. Because he is extremely allergic, he suffers an <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">anaphylactic reaction<\/mark><\/strong> that leads to his death.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">As illustrated in the film, <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">Hymenoptera<\/mark><\/strong> stings can be potentially fatal due to the risk of <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">anaphylaxis<\/mark><\/strong>. <strong>Anaphylaxis<\/strong> is an exaggerated <strong>allergic reaction<\/strong> that some patients may experience. It may involve a <strong>sudden drop in blood pressure, shortness of breath due to airway constriction, swelling, redness and itching of the skin (urticaria)<\/strong>, and the <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">risk of death within minutes<\/mark><\/strong>.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">The film portrays a real <strong>clinical problem<\/strong> investigated by the research group in studies initiated by <strong>Prof. Zollner<\/strong> in patients who presented this type of response. The group focused on exploring both the venom components that trigger these reactions, known as <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">allergens<\/mark><\/strong>, and the immune response mechanisms involved in this process.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center eplus-wrapper has-vivid-cyan-blue-color has-text-color has-link-color has-large-font-size wp-elements-964885bdc951bec6d458eb2ae5908aea\">The limits of current therapies for venom allergies<\/h2>\n\n\n\n<p class=\"eplus-wrapper\">Currently, the <strong>treatment<\/strong> of anaphylaxis has some limitations. Prof. Lu\u00eds explains: \u201cWhen a patient experiences this condition, they are treated with drugs that mainly act on the symptoms: they stabilize the patient and block the anaphylactic reaction, but they do not modify the response over time. There is <strong>a way to modify this response<\/strong>, which we call <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">immunotherapy<\/mark><\/strong>.\u201d <strong>Immunotherapy<\/strong> uses the venom itself to treat the allergic response to the venom. Over time, it can <strong>shift the immune response<\/strong> toward a non-harmful profile. Thus, if the individual is stung again, they may still experience reactions, but the condition will be milder, <strong>reducing the risk of death<\/strong>.<\/p>\n\n\n\n<p class=\"eplus-wrapper\"><strong>Immunotherapy<\/strong> is already used in some parts of the world, but it still needs improvement. <strong>Adverse effects<\/strong> may occur as a result of venom administration, such as <strong>exaggerated reactions<\/strong> during treatment in some patients and the induction of <strong>harmful responses<\/strong> to other venom components to which the patient had not previously reacted, a phenomenon known as <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">sensitization to new allergens<\/mark><\/strong>.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">For this reason, in his FAPESP-funded project, Prof. Lu\u00eds seeks to improve immunotherapy through an approach aimed at reducing these adverse effects. He explains: \u201cThe idea is to generate the main components of the venom that modulate the response: the allergens. We want to produce modified allergens capable of modulating the immune response without triggering unwanted reactions. This strategy is called the use of <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">hypoallergenic variants<\/mark><\/strong>.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center eplus-wrapper has-vivid-cyan-blue-color has-text-color has-link-color has-large-font-size wp-elements-9344fe9f29bafc4d16e0f79cd7c46500\">Rewriting the \u201crecipe\u201d of venom<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large eplus-wrapper\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-content\/uploads\/sites\/303\/2026\/03\/Fig-1-1024x576.png\" alt=\"\" class=\"wp-image-530\" srcset=\"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-content\/uploads\/sites\/303\/2026\/03\/Fig-1-980x551.png 980w, https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-content\/uploads\/sites\/303\/2026\/03\/Fig-1-480x270.png 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n\n\n\n<p class=\"eplus-wrapper\">Researchers can now <strong>produce venom allergens in the laboratory without needing the wasp itself<\/strong>. Prof. Lu\u00eds explains how the process works: \u201cWe extract <strong>RNA from the venom glands of wasps<\/strong>, locate the <strong>allergen gene<\/strong>, and clone this gene into <strong>expression vectors<\/strong>.\u201d<\/p>\n\n\n\n<p class=\"eplus-wrapper\">This process is similar to obtaining a copy of the <strong>\u201crecipe book\u201d<\/strong> that wasps use to produce the components of their venom: the <strong>cDNA<\/strong> obtained from the <strong>messenger RNA<\/strong> of the venom glands. Researchers then identify only the pages containing the <strong>\u201crecipes\u201d<\/strong> of interest: the <strong>specific allergen genes<\/strong>. Finally, these recipes are given to other <strong>\u201ccooks\u201d<\/strong> to produce the allergens: the <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">expression vectors<\/mark><\/strong>. These vectors may be bacteria (such as <em>Escherichia coli<\/em>), yeast cells, or even cells from other insects.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">Once the gene has been cloned, researchers can introduce mutations through <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">genetic engineering<\/mark><\/strong> to obtain <strong>hypoallergenic variants<\/strong>. The key step is identifying the <strong>region of the allergen molecule<\/strong> known as the <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">epitope<\/mark><\/strong>. This is the region where a type of antibody produced by the patient, called <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">immunoglobulin E (IgE)<\/mark><\/strong>, binds. <strong>This binding is the first step in triggering the anaphylactic response<\/strong>. Therefore, locating the epitopes is essential. If the allergen molecule is modified so that this epitope is no longer present, IgE binding will not occur and, consequently, the anaphylactic reaction will not be triggered. This is how <strong>hypoallergenic variants<\/strong> are created: allergen molecules modified to avoid triggering an unwanted immune response.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">Returning to the recipe-book metaphor, introducing these mutations is similar to modifying a recipe. Researchers must identify the part of the gene responsible for producing the epitope, just as one would identify the part of a recipe that instructs adding a specific ingredient. If that ingredient is undesirable, the recipe can be altered by removing it or replacing it with another. This modification corresponds to a <strong>genetic mutation<\/strong>. In this way, a recipe (<strong>gene<\/strong>) that once instructed the preparation of a cornmeal cake with anise seeds (<strong>the original allergen<\/strong>) could be modified to remove the anise (<strong>the epitope<\/strong>), resulting in a plain cornmeal cake (<strong>the hypoallergenic variant<\/strong>).<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center eplus-wrapper has-vivid-cyan-blue-color has-text-color has-link-color has-large-font-size wp-elements-b0819502c0effd30dc5eb19925e8d01e\">Why studying Brazilian wasps is important<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large eplus-wrapper\"><img decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-content\/uploads\/sites\/303\/2026\/03\/Fig-2-1024x576.png\" alt=\"\" class=\"wp-image-531\" srcset=\"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-content\/uploads\/sites\/303\/2026\/03\/Fig-2-980x551.png 980w, https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-content\/uploads\/sites\/303\/2026\/03\/Fig-2-480x270.png 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><figcaption class=\"wp-element-caption\"><mark style=\"background-color:#ffffff\" class=\"has-inline-color has-cyan-bluish-gray-color\"><em>Polybia paulista<\/em>&nbsp;(source: Wikipedia Commons).<\/mark><\/figcaption><\/figure>\n\n\n\n<p class=\"eplus-wrapper\">One major interest of the study is the possibility of creating <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">immunotherapeutic products <\/mark><\/strong>with potential future clinical applications in immunotherapy protocols. Currently, treatment relies on<strong> imported <\/strong>immunotherapeutic products, which <strong>significantly increases costs<\/strong>.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">Another important aspect is the use of wasp species prevalent in Brazil. At present, <strong>immunotherapy is performed using venom from wasps common in other countries<\/strong>, such as the yellow jacket wasp from the United States. In his project, however, Prof. Lu\u00eds uses allergens derived from the venom of the wasp <em><strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">Polybia paulista<\/mark><\/strong><\/em> (locally known as <strong>\u201cmarimbondo-paulistinha\u201d<\/strong>), a species known for the frequency of accidents, especially due to its aggressiveness and adaptation to urban environments. It can be found in the Brazilian states of S\u00e3o Paulo, Minas Gerais, Goi\u00e1s, Mato Grosso, and Paran\u00e1, as well as in other Latin American countries such as Argentina.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">The allergens selected to generate the hypoallergenic variants are <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">Poly p 1<\/mark><\/strong> and <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">Poly p 5<\/mark><\/strong> from <em>Polybia paulista<\/em> venom. Prof. Lu\u00eds\u2019s research group, in collaboration with <a href=\"https:\/\/lattes.cnpq.br\/2901888624506535\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/lattes.cnpq.br\/2901888624506535\" rel=\"noreferrer noopener\">Prof. Dr. Mario Sergio Palma<\/a> and the now-retired <a href=\"https:\/\/lattes.cnpq.br\/0316857632230804\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/lattes.cnpq.br\/0316857632230804\" rel=\"noreferrer noopener\">Prof. Dr. M\u00e1rcia Regina Brochetto Braga<\/a>, both from the Institute of <strong>Biosciences in Rio Claro (UNESP)<\/strong>, performed <strong>immunological and biochemical characterization<\/strong> of these allergens in their <strong>natural and recombinant forms<\/strong> expressed in yeast. These are the <strong>allergens that most frequently cause anaphylactic reactions in the venom<\/strong>.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">Another factor that may aggravate cases of anaphylaxis is <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">climate change<\/mark><\/strong>. Prof. Lu\u00eds warns that cases of <strong>wasp stings are increasingly being reported in new regions<\/strong>: \u201cCases of anaphylaxis have already been described in Alaska. [&#8230;] Changes caused by global warming are leading colder countries to begin reporting accidents involving species that were previously not found there.\u201d As a result,<strong> more stings<\/strong> from species such as <em>Polybia paulista<\/em> and, consequently, <strong>more cases of anaphylaxis may occur in the future<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center eplus-wrapper has-vivid-cyan-blue-color has-text-color has-link-color has-large-font-size wp-elements-eb688e9599bdb221dd589b3b23e02746\">From the laboratory to potential clinical application<\/h2>\n\n\n\n<p class=\"eplus-wrapper\">If the use of hypoallergenic variants in the immunotherapy prove to be safe, the<strong>future is promising<\/strong>. Prof. Lu\u00eds explains: \u201cWe aim to transform this biotechnological product into a <strong>new pharmaceutical formulation<\/strong>. There is great potential for <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">patent generation<\/mark><\/strong>. Contacts with <a href=\"https:\/\/www.inova.unicamp.br\/\" data-type=\"link\" data-id=\"https:\/\/www.inova.unicamp.br\/\" target=\"_blank\" rel=\"noreferrer noopener\">Inova<\/a> (UNICAMP\u2019s Innovation Agency) are already underway.\u201d However, he emphasizes that <strong>many studies are still required<\/strong> before a patent can be filed. At the moment,<strong><em>in vitro<\/em> studies<\/strong> (without the use of animals) and <strong>experiments in laboratory animals<\/strong> (mice) are being conducted. <strong>Only then will the project be able to move forward to clinical trials in humans.<\/strong><\/p>\n\n\n\n<p class=\"eplus-wrapper\">Prof. Lu\u00eds also highlights the importance of using experimental animals: \u201cI would love to have an artificial or in vitro system capable of mimicking the full complexity of the anaphylactic response. <strong>Unfortunately, we still do not have models that can fully replace the use of animals<\/strong>.\u201d The group uses well-established models of anaphylactic response with BALB\/c mice, which, when exposed to venom, produce a <strong>Th2-type response<\/strong> similar to that observed in allergic individuals.<\/p>\n\n\n\n<p class=\"eplus-wrapper\">At present, another major focus of the research is ensuring the <strong>safety<\/strong> of the hypoallergenic variants in immunotherapy. Prof. Lu\u00eds notes: \u201cAnother important point our project aims to evaluate is the <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">toxicity<\/mark><\/strong> of these compounds. [&#8230;] One of the toxic effects of Hymenoptera venoms is <strong>kidney injury<\/strong>.\u201d The laboratory is located at the <strong>Integrated Center for Nephrology<\/strong>. In collaboration with <a href=\"https:\/\/lattes.cnpq.br\/7908107722945137\" data-type=\"link\" data-id=\"https:\/\/lattes.cnpq.br\/7908107722945137\" target=\"_blank\" rel=\"noreferrer noopener\">Prof. Dr. Marilda Mazzali<\/a>, coordinator of the <strong>Laboratory for Transplantation Research<\/strong>, and <a href=\"https:\/\/lattes.cnpq.br\/6666579120473312\" data-type=\"link\" data-id=\"https:\/\/lattes.cnpq.br\/6666579120473312\" target=\"_blank\" rel=\"noreferrer noopener\">Prof. Dr. Marcos Vinicius de Sousa<\/a>, both nephrologists, the group will evaluate renal toxicity in an experimental mouse model. <strong>Only after the variants are proven safe in animal models will studies advance to humans.<\/strong><\/p>\n\n\n\n<p class=\"eplus-wrapper\"><strong>The project is currently in the epitope localization stage<\/strong>. Preliminary results on the in vitro production of allergens were presented in October 2025 at the <a href=\"https:\/\/immuno2025.sbi.org.br\/\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/immuno2025.sbi.org.br\/\" rel=\"noreferrer noopener\">XLIX Congress of the Brazilian Society of Immunology<\/a> (B\u00fazios, Rio de Janeiro) by <a href=\"https:\/\/lattes.cnpq.br\/1413310048066249\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/lattes.cnpq.br\/1413310048066249\" rel=\"noreferrer noopener\">La\u00eds Stephanie Minati<\/a> (master\u2019s student) and <a href=\"https:\/\/lattes.cnpq.br\/4400493514376374\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/lattes.cnpq.br\/4400493514376374\" rel=\"noreferrer noopener\">Juliana de Assis Chagas<\/a> (undergraduate research student). Other students funded by FAPESP directly involved in the project include <a href=\"https:\/\/lattes.cnpq.br\/8793724685102413\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/lattes.cnpq.br\/8793724685102413\" rel=\"noreferrer noopener\">Beatriz Pinheiro Furlanetto<\/a> (undergraduate research fellowship, process no. <a href=\"https:\/\/bv.fapesp.br\/pt\/bolsas\/230579\/mapeamento-dos-epitopos-dos-principais-alergenos-do-veneno-da-vespa-polybia-paulista-poly-p-1-e-poly\/?q=25\/14584-1\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/bv.fapesp.br\/pt\/bolsas\/230579\/mapeamento-dos-epitopos-dos-principais-alergenos-do-veneno-da-vespa-polybia-paulista-poly-p-1-e-poly\/?q=25\/14584-1\" rel=\"noreferrer noopener\">25\/14584-1<\/a>) and <a href=\"https:\/\/lattes.cnpq.br\/9508328531769037\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/lattes.cnpq.br\/9508328531769037\" rel=\"noreferrer noopener\">Milena Fajani Franchikoski <\/a>(technical training fellowship, process no. <a href=\"https:\/\/bv.fapesp.br\/pt\/bolsas\/232276\/obtencao-das-formas-recombinantes-dos-alergenos-poly-p-1-e-poly-p-5-do-veneno-de-polybia-paulista-e-\/?q=25\/20426-0\" target=\"_blank\" data-type=\"link\" data-id=\"https:\/\/bv.fapesp.br\/pt\/bolsas\/232276\/obtencao-das-formas-recombinantes-dos-alergenos-poly-p-1-e-poly-p-5-do-veneno-de-polybia-paulista-e-\/?q=25\/20426-0\" rel=\"noreferrer noopener\">25\/20426-0<\/a>).<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center eplus-wrapper has-vivid-cyan-blue-color has-text-color has-link-color has-large-font-size wp-elements-0a444a33e16bf11cf98c7a5c1bcdaf7a\">The group is opening positions for new researchers<\/h2>\n\n\n\n<p class=\"eplus-wrapper\">Prof. Lu\u00eds is <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">currently looking for new researchers interested in joining his group<\/mark><\/strong>. The <strong>FAPESP research grant includes<\/strong> <strong>TT-1 and TT-3 fellowships<\/strong> (Technical Training levels 1 and 3). For these opportunities, the professor is seeking individuals who are currently pursuing (TT-1) or have already completed (TT-3) undergraduate degrees in biological sciences. He is also looking for prospective <strong>master\u2019s and doctoral students<\/strong>.<\/p>\n\n\n\n<p class=\"eplus-wrapper\"><strong>Requirements<\/strong> include basic undergraduate-level knowledge of Immunology and Molecular Biology; proficiency in basic laboratory techniques (pipetting, principles of immunoassays and molecular analyses, etc.); and a willingness to learn. Candidates are expected to have a <strong>curious and proactive profile <\/strong>when searching for new articles, techniques, and experimental approaches. <strong>Interested individuals should contact luisgrf@unicamp.br by email.<\/strong><\/p>\n\n\n\n<p class=\"eplus-wrapper\">By investing in <strong><mark style=\"background-color:#8ed1fc\" class=\"has-inline-color has-black-color\">hypoallergenic variants<\/mark><\/strong>, Prof. Lu\u00eds\u2019s research aims to improve the immunotherapy, making it <strong>safer and more accessible<\/strong>. Furthermore, the project contributes to building a strategic path for <strong>Brazilian science<\/strong>: <strong>developing technologies and solutions adapted to our epidemiological reality while strengthening national scientific and pharmaceutical autonomy<\/strong>. Initiatives like this demonstrate how <strong>basic and translational research can lead to concrete innovation with real potential to save lives<\/strong>.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>This article was produced with the support of the S\u00e3o Paulo Research Foundation (FAPESP), Brazil. Grant No. 25\/17158-3. The opinions, hypotheses, conclusions, or recommendations expressed in this material are the responsibility of the author(s) and do not necessarily reflect the views of FAPESP.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"eplus-wrapper has-large-font-size\"><strong>To learn more:<\/strong><\/p>\n\n\n\n<p class=\"eplus-wrapper\"><a href=\"http:\/\/www.sbai.org.br\/secao.asp?s=81&amp;id=298\" target=\"_blank\" data-type=\"link\" data-id=\"http:\/\/www.sbai.org.br\/secao.asp?s=81&amp;id=298\" rel=\"noreferrer noopener\">Immunotherapy<\/a><\/p>\n\n\n\n<p class=\"eplus-wrapper\"><em><a href=\"https:\/\/www.academia.edu\/111727604\/Ocorr%C3%AAncia_De_Acidentes_Causados_Por_Ferroadas_De_Vespas_Na_Cidade_De_Ponta_Grossa_Paran%C3%A1?uc-sb-sw=7338042\" data-type=\"link\" data-id=\"https:\/\/www.academia.edu\/111727604\/Ocorr%C3%AAncia_De_Acidentes_Causados_Por_Ferroadas_De_Vespas_Na_Cidade_De_Ponta_Grossa_Paran%C3%A1?uc-sb-sw=7338042\" target=\"_blank\" rel=\"noreferrer noopener\">Polybia paulista<\/a><\/em> (DOI: 10.5212\/PUBL.BIOLOGICAS.V.26.I1.0001)<\/p>\n\n\n\n<p class=\"eplus-wrapper\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27826019\/\" data-type=\"link\" data-id=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27826019\/\" target=\"_blank\" rel=\"noreferrer noopener\">Poly p 1<\/a> (DOI: 10.1016\/j.toxicon.2016.11.006)<\/p>\n\n\n\n<p class=\"eplus-wrapper\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34941688\/\" data-type=\"link\" data-id=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34941688\/\" target=\"_blank\" rel=\"noreferrer noopener\">Poly p 5 <\/a>(paper 1) (DOI: 10.3390\/toxins13120850)<\/p>\n\n\n\n<p class=\"eplus-wrapper\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28837089\/\" data-type=\"link\" data-id=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28837089\/\" target=\"_blank\" rel=\"noreferrer noopener\">Poly p 5<\/a> (paper 2) (DOI: 10.3390\/toxins9090259)<\/p>\n\n\n\n<h2 class=\"wp-block-heading eplus-wrapper has-vivid-green-cyan-color has-text-color has-link-color has-large-font-size wp-elements-bae3f0e8ac3d88d20f663766889c1d03\"><strong>Written by:<\/strong><\/h2>\n\n\n<div class=\"wp-block-image eplus-wrapper\">\n<figure class=\"aligncenter size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-content\/uploads\/sites\/303\/2026\/02\/Design-sem-nome-3-1024x1024.png\" alt=\"\" class=\"wp-image-258\" style=\"width:150px\" srcset=\"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-content\/uploads\/sites\/303\/2026\/02\/Design-sem-nome-3-980x980.png 980w, https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-content\/uploads\/sites\/303\/2026\/02\/Design-sem-nome-3-480x480.png 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n<\/div>\n\n\n<p class=\"has-text-align-center eplus-wrapper has-vivid-green-cyan-color has-text-color has-link-color wp-elements-68e100116878e361fbaa90b834c0f522\"><strong>Mia Schezaro Ramos<\/strong><br>Pharmacist. Ph.D. in Pharmacology. Science journalist, illustrator, trans, Nintendo enthusiast, K-pop fan, and dependent on physical exercise to stay sane.<\/p>\n\n\n\n<p class=\"eplus-wrapper\"><\/p>\n\n\n\n<p class=\"eplus-wrapper\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>UNICAMP research aims to improve immunotherapy for wasp venom allergy by developing hypoallergenic variants of Polybia paulista allergens, potentially reducing adverse reactions and expanding access to safer treatments.<\/p>\n","protected":false},"author":776,"featured_media":524,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_eb_attr":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"pgc_sgb_lightbox_settings":"","_vp_format_video_url":"","_vp_image_focal_point":[],"footnotes":""},"categories":[18,31,30],"tags":[],"class_list":["post-536","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-english","category-open-doors","category-research"],"_links":{"self":[{"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/posts\/536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/users\/776"}],"replies":[{"embeddable":true,"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/comments?post=536"}],"version-history":[{"count":8,"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/posts\/536\/revisions"}],"predecessor-version":[{"id":787,"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/posts\/536\/revisions\/787"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/media\/524"}],"wp:attachment":[{"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/media?parent=536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/categories?post=536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.blogs.unicamp.br\/farmacoemfoco\/wp-json\/wp\/v2\/tags?post=536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}